rosiglitazone has been researched along with Carcinoma, Papillary in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Honsawek, S; Keelawat, S; Ruangvejvorachai, P; Tepmongkol, S | 1 |
| Cambil, T; Castro, J; MartÃn, T; Torres, A | 1 |
| Clark, OH; Greenspan, FS; Hawkins, R; Kebebew, E; Lindsay, S; Woeber, KA | 1 |
| Endo, T; Haraguchi, K; Hershman, JM; Ohta, K; Onaya, T | 1 |
1 trial(s) available for rosiglitazone and Carcinoma, Papillary
| Article | Year |
|---|---|
Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Dose-Response Relationship, Drug; Female; Humans; Iodine; Iodine Radioisotopes; Male; Middle Aged; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Neoplasms; Whole Body Imaging | 2008 |
3 other study(ies) available for rosiglitazone and Carcinoma, Papillary
| Article | Year |
|---|---|
[Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
Topics: Carcinoma, Papillary; Female; Fibrinolytic Agents; Humans; Hypoglycemic Agents; Iodine Radioisotopes; Middle Aged; Neoplasm Staging; Positron-Emission Tomography; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms | 2008 |
Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer.
Topics: Adult; Carcinoma, Papillary; Combined Modality Therapy; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Thyroglobulin; Thyroid Gland; Thyroid Neoplasms | 2009 |
Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Carcinoma, Papillary; Cell Division; Chromans; Humans; Male; Mice; Mice, Inbred BALB C; Receptors, Cytoplasmic and Nuclear; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Rosiglitazone; Thiazoles; Thiazolidinediones; Thymidine; Thyroid Neoplasms; Transcription Factors; Troglitazone; Tumor Cells, Cultured | 2001 |